Understanding how U2AF1 mutations contribute to myelodysplastic syndrome
Official title: Distinct roles of U2AF1 mutations in myelodysplastic syndrome pathogenesis
Funded at University of Colorado Denver · NIH-10873169 · Data updated 2026-11-12
This study is looking into how changes in the U2AF1 gene affect people with myelodysplastic syndrome (MDS), which could help us find better ways to diagnose and treat this blood disorder.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | July 9, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $162,828 |
| NIH project number | 5K08HL159354-04 |
| Project ID | NIH-10873169 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with myelodysplastic syndrome, particularly those with U2AF1 mutations.
✕Less likely to help
Patients without myelodysplastic syndrome or those not carrying U2AF1 mutations may not benefit from this research.
What this research studies
This research investigates the specific roles of U2AF1 mutations in the development of myelodysplastic syndrome (MDS), a type of blood disorder. The project aims to clarify how different mutations in the U2AF1 gene affect the disease's progression and patient outcomes. By utilizing advanced laboratory techniques and collaborating with experts in the field, the research seeks to uncover the molecular mechanisms behind these mutations. This could lead to better diagnostic and therapeutic strategies for patients with MDS.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with myelodysplastic syndrome.
How similar studies have gone: Previous research has shown promising results in understanding the role of genetic mutations in blood disorders, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Alberti, Michael O — University of Colorado Denver
- Study coordinator: Alberti, Michael O
Related research
Other NIH-funded projects on the same topics.
-
Targeting diverse stem cells in myelodysplastic syndrome to eradicate the disease
Aimed at identifying weaknesses in the diverse stem cell populations of myelodysplastic syndrome so future treatments can wipe out the root cause of the disease.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
-
Targeting metabolic weak spots in myelodysplastic syndrome stem cells
The team is trying metabolism-based treatments to kill the stem cells that drive high-risk myelodysplastic syndrome (MDS).
-
Investigating the role of PI3 kinase in Myelodysplastic Syndrome
This study is looking at how certain changes in genes might affect blood cell production in older adults with Myelodysplastic Syndrome (MDS), and it hopes to find new ways to help improve treatment for people with this condition.
-
Identifying harmful and harmless genetic variations in blood cancer predisposition genes
This study is looking at how certain changes in a gene called DDX41 might affect the chances of developing blood disorders like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), so that doctors can provide better advice and support for patients at risk.
-
Investigating CCRL2's role in myelodysplastic syndrome
This study is looking at how a specific gene called CCRL2 affects the growth of harmful cells in myelodysplastic syndrome (MDS), especially in men, to find new ways to improve treatment for people with this blood disorder.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.